Substance Abuse & Addiction
Search All News
Columbia Psychiatry's Caroline Arout uses quantitative sensory testing, or QST, for assessing the effectiveness of cannabis for therapeutic uses.
“Our study provides further evidence that marijuana use is not effective in reducing nonmedical opioid use,” said study author Dr. Mark Olfson.
Source:New York Times
Marijuana, Dr. Margaret Haney, said, “reduces reaction time and has other effects that would worsen performance.”
Source:Psychiatric TimesMarch 19, 2021
Dr. Lloyd Sederer provides key insights on what we can do to save more lives from overdose deaths.
Source:MIC.COMMarch 3, 2021
“The more people who are vocal about their drug use, we, as a society, will become less likely to vilify people for what they do with their bodies," says Dr. Carl Hart.
Source:InsiderMarch 1, 2021
"It is important to know that change takes time. Progress is not always linear; relapses or slips are often a part of the process," says Dr. Aimee Chiligiris.
Source:Wall Street JournalJanuary 13, 2021
Dr. Sally Satel reviews Dr. Carl Hart's "“Drug Use for Grown-Ups," in which he asserts “recreational drugs can be used safely to enhance many vital human activities.”
Source:MedscapeDecember 15, 2020
"[Buprenorphine] is a tremendously powerful medication, saves many lives and prevents overdose, but there is a risk of misuse and diversion, albeit pretty low," says Dr. Francis Levin.
Source:HealthlineDecember 1, 2020
“I honestly find that most Americans do not think that cannabis can produce dependence, and so I think that’s the first step, knowing that there’s that potential,” says Margaret Haney, PhD
- November 16, 2020
The Substance Abuse and Mental Health Services Administration has awarded $32 million to the American Academy of Addiction Psychiatry to address opioid use disorders and stimulant use disorders.
- November 13, 2020
This year’s Eric D. Hadar Distinguished Lecture will take place on November 18th, 2020 with Dr. Dorothy Hatsukami, who will present, “Tobacco Harm Reduction: Controversies and a Path Forward.”
- June 3, 2020
“More than any other provider group, primary care providers offer greater potential for expanding access to buprenorphine treatment,” says Dr. Mark Olfson.
Source:MedscapeMay 18, 2020
We are currently dealing with the "triple trouble" of a pandemic, unemployment, and diminished personal and community supports writes Dr. Lloyd Sederer.